DC
TGTX icon

Davenport & Co’s TG Therapeutics TGTX Stock Holding History

Davenport & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,200
Closed -$72K – 1042
2022
Q3 		$72K Buy
+12,200
New +$80K ﹤0.01% 971
2021
Q4 		– Sell
-9,305
Closed -$309K – 1116
2021
Q3 		$309K Hold
9,305
– – ﹤0.01% 847
2021
Q2 		$360K Buy
9,305
+20
+0.2% +$785 ﹤0.01% 738
2021
Q1 		$448K Hold
9,285
– – ﹤0.01% 554
2020
Q4 		$483K Buy
9,285
+585
+7% +$19.8K ﹤0.01% 530
2020
Q3 		$233K Sell
8,700
-2,000
-19% -$46K ﹤0.01% 641
2020
Q2 		$208K Buy
+10,700
New +$172K ﹤0.01% 640

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Davenport & Co's TGTX Position: Q4 2022 in Review

Davenport & Co sold out of TG Therapeutics (TGTX) in Q4 2022, closing a stake of 12,200 shares — an estimated $72K sold.

Davenport & Co first reported a position in TGTX in Q2 2020 and held it in 7 quarters. The position peaked at $483K in Q4 2020. 198 funds tracked by Wall St. Rank hold TGTX as of Q4 2022.

  • Davenport & Co reported no remaining TG Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Davenport & Co sold 12,200 TG Therapeutics shares in Q4 2022, an estimated $72K.
  • Davenport & Co first reported a position in TG Therapeutics in Q2 2020 and held it in 7 quarters.
  • Davenport & Co's TG Therapeutics position peaked at $483K in Q4 2020.
  • 198 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2022.

Based on Davenport & Co's 13F filing for Q4 2022, filed 20 Jan 2023.